In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis, model

被引：95

作者：

Jacqueline, Cedric

Caillon, Jocelyne

Le Mabecque, Virqime

Miegeville, Anne-Francoise

Hamel, Antoine

Bugnon, Denis

Ge, James Yigong

Potell, Gilles

机构：

[1] Univ Nantes, Nantes Atlantique Univ, UFR Med, EA3826, F-44035 Nantes, France

[2] Cerexa Inc, Alameda, CA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 09期

关键词：

INFECTION MODELS; INFUSION; AFFINITY;

D O I：

10.1128/AAC.01242-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of linezolid and vancomycin against methicillin-resistant Staphylococcus aureus. After a 4-day treatment, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S. aureus strain.

引用

收藏

页码：3397 / 3400

页数：4

相关论文

共 18 条

[1]

Amsterdam D., 1996, ANTIBIOTICS LAB MED, V4th, P52

[2] Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models:: Identification of an in vivo pharmacokinetic-pharmacodynamic target [J].

Andes, D ;

Craig, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1376-1383

[3]

[Anonymous], 46 INT C ANT AG CHEM

[4] Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model:: MICs do not predict in vivo efficacy [J].

Asseray, N ;

Jacqueline, C ;

Le Mabecque, V ;

Batard, E ;

Bugnon, D ;

Potel, G ;

Caillon, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :857-859

[5] Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus [J].

Chambers, HF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :884-888

[6]

DURACK DT, 1972, BRIT J EXP PATHOL, V53, P50

[7]

Iizawa Yuji, 2004, Journal of Infection and Chemotherapy, V10, P146

[8] In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus [J].

Jacqueline, C ;

Navas, D ;

Batard, E ;

Miegeville, AF ;

Le Mabecque, V ;

Kergueris, MF ;

Bugnon, D ;

Potel, G ;

Caillon, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :45-51

[9] In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model [J].

Jacqueline, C ;

Batard, E ;

Perez, L ;

Boutoille, D ;

Hamel, A ;

Caillon, J ;

Kergueris, MF ;

Potel, G ;

Bugnon, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) :3706-3711

[10] RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases [J].

Malouin, F ;

Blais, J ;

Chamberland, S ;

Hoang, M ;

Park, C ;

Chan, C ;

Mathias, K ;

Hakem, S ;

Dupree, K ;

Liu, E ;

Nguyen, T ;

Dudley, MN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :658-664